Olympus to Acquire BioProtect for Prostate Cancer Care
TOKYO, Japan, May 26, 2026 Olympus Corporation has announced a definitive agreement to acquire BioProtect Ltd., an Israel-based medical...
ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
TOKYO, Japan, May 26, 2026 Olympus Corporation has announced a definitive agreement to acquire BioProtect Ltd., an Israel-based medical...
HANGZHOU, China and BERLIN, January 16, 2026 — Zylox-Tonbridge, a Hong Kong–listed medical technology company focused on neurovascular and...
